Works by Ozcan, M.

Results: 220
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19

    Yineleyici Multipl Skleroz'da Kognitif Bozukluk.

    Published in:
    Archives of Neuropsychiatry / Nöropsikiyatri Arşivi, 2012, v. 49, n. 3, p. 178, doi. 10.4274/npa.y6089
    By:
    • TOPÇULAR, Barış;
    • Emin ÖZCAN, M.;
    • KURT, Elif;
    • YANDIM KUŞÇU, Demet;
    • KALE İÇEN, Nilüfer;
    • Nevin SÜTLAŞ, Pakize;
    • KIRBAŞ, Dursun;
    • BİNGÖL, Ayhan
    Publication type:
    Article
    20
    21
    22
    23
    24
    25
    26
    27
    28

    Phase 2 KEYNOTE‐B68 study: pembrolizumab every 6 weeks in relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) or primary mediastinal B‐cell lymphoma (PMBCL).

    Published in:
    Hematological Oncology, 2023, v. 41, p. 575, doi. 10.1002/hon.3164_431
    By:
    • McDonald, A.;
    • Verburgh, E.;
    • Gotti, M.;
    • Pinto, A.;
    • Zaucha, J.;
    • Ivanov, V.;
    • Melnichenko, V.;
    • Mocikova, H.;
    • Ozcan, M.;
    • Patti, C.;
    • Farias, J.;
    • Goncalves, I.;
    • Kuchkova, O.;
    • Mayer, J.;
    • Saydam, G.;
    • Tomassetti, S.;
    • Pathiraja, K.;
    • Ryland, K.;
    • Chakraborty, S.;
    • Jurczak, W.
    Publication type:
    Article
    29

    A phase 2 study of zilovertamab vedotin as monotherapy or in combination in patients (pts) with aggressive and indolent B‐cell malignancies: waveLINE‐006.

    Published in:
    Hematological Oncology, 2023, v. 41, p. 564, doi. 10.1002/hon.3164_422
    By:
    • Zinzani, P. L.;
    • Mayer, J.;
    • Benjamini, O.;
    • Berkovits, A.;
    • Glimelius, I.;
    • Stevens, D.;
    • Chaudhry, A.;
    • Demir, A. M.;
    • Sanz, R. G.;
    • Kim, W. S.;
    • Li, F.;
    • Halka, J.;
    • Marin‐Niebla, A.;
    • Ozcan, M.;
    • Paszkiewicz‐Kozik, E.;
    • Santoro, A.;
    • Ren, Y.;
    • Ogbu, U.;
    • Marinello, P.;
    • Jurczak, W.
    Publication type:
    Article
    30
    31
    32
    33

    HEALTH‐RELATED QUALITY OF LIFE AMONG PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL) IN A PHASE 3 STUDY OF PEMBROLIZUMAB VERSUS BRENTUXIMAB VEDOTIN.

    Published in:
    Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.105_2880
    By:
    • Zinzani, P. L.;
    • Raut, M.;
    • Saretsky, T.;
    • Ramchandren, R.;
    • Santoro, A.;
    • Paszkiewicz‐Kozik, E.;
    • Gasiorowski, R.;
    • Johnson, N. A.;
    • de Oliveira, J. S. R.;
    • Buccheri, V.;
    • Perini, G. F.;
    • Dickinson, M.;
    • McDonald, A.;
    • Ozcan, M.;
    • Sekiguchi, N.;
    • Giezek, H.;
    • Nahar, A.;
    • Kuruvilla, J.
    Publication type:
    Article
    34
    35
    36

    ROBUST: First report of phase III randomized study of lenalidomide/R‐CHOP (R<sup>2</sup>‐CHOP) vs placebo/R‐CHOP in previously untreated ABC‐type diffuse large B‐cell lymphoma.

    Published in:
    Hematological Oncology, 2019, v. 37, p. 36, doi. 10.1002/hon.5_2629
    By:
    • Vitolo, U.;
    • Witzig, T.E.;
    • Gascoyne, R.D.;
    • Scott, D.W.;
    • Zhang, Q.;
    • Jurczak, W.;
    • Özcan, M.;
    • Hong, X.;
    • Zhu, J.;
    • Jin, J.;
    • Belada, D.;
    • Bergua, J.M.;
    • Piazza, F.;
    • Mócikova, H.;
    • Molinari, A.L.;
    • Yoon, D.H.;
    • Cavallo, F.;
    • Tani, M.;
    • Izutsu, K.;
    • Kato, K.
    Publication type:
    Article
    37
    38
    39

    ROBUST: First report of phase III randomized study of lenalidomide/R‐CHOP (R<sup>2</sup>‐CHOP) vs placebo/R‐CHOP in previously untreated ABC‐type diffuse large B‐cell lymphoma.

    Published in:
    Hematological Oncology, 2019, v. 37, p. 36, doi. 10.1002/hon.5_2629
    By:
    • Vitolo, U.;
    • Witzig, T.E.;
    • Gascoyne, R.D.;
    • Scott, D.W.;
    • Zhang, Q.;
    • Jurczak, W.;
    • Özcan, M.;
    • Hong, X.;
    • Zhu, J.;
    • Jin, J.;
    • Belada, D.;
    • Bergua, J.M.;
    • Piazza, F.;
    • Mócikova, H.;
    • Molinari, A.L.;
    • Yoon, D.H.;
    • Cavallo, F.;
    • Tani, M.;
    • Izutsu, K.;
    • Kato, K.
    Publication type:
    Article
    40

    COPANLISIB IN PATIENTS WITH RELAPSED OR REFRACTORY INDOLENT B-CELL LYMPHOMA (CHRONOS-1).

    Published in:
    Hematological Oncology, 2017, v. 35, p. 119, doi. 10.1002/hon.2437_107
    By:
    • Dreyling, M.;
    • Santoro, A.;
    • Mollica, L.;
    • Leppä, S.;
    • Follows, G.A.;
    • Lenz, G.;
    • Kim, W.;
    • Nagler, A.;
    • Panayiotidis, P.;
    • Demeter, J.;
    • Özcan, M.;
    • Kosinova, M.;
    • Bouabdallah, K.;
    • Morschhauser, F.;
    • Stevens, D.A.;
    • Trevarthen, D.;
    • Giurescu, M.;
    • Liu, L.;
    • Koechert, K.;
    • Peña, C.
    Publication type:
    Article
    41

    Efficacy and safety of pembrolizumab in relapsed/refractory primary mediastinal large B-cell lymphoma (rrPMBCL): interim analysis of the KEYNOTE-170 phase 2 trial.

    Published in:
    Hematological Oncology, 2017, v. 35, p. 62, doi. 10.1002/hon.2437_49
    By:
    • Zinzani, P.;
    • Thieblemont, C.;
    • Melnichenko, V.;
    • Osmanov, D.;
    • Bouabdallah, K.;
    • Walewski, J.;
    • Majlis, A.;
    • Fogliatto, L.;
    • Caballero Barrigón, M.D.;
    • Christian, B.;
    • Gulbas, Z.;
    • Özcan, M.;
    • Salles, G.A.;
    • Shipp, M.A.;
    • Balakumaran, A.;
    • Chlosta, S.;
    • Chatterjee, A.;
    • Armand, P.
    Publication type:
    Article
    42
    43
    44
    45

    Lack of Prognostic Value of CD34 in Adult AML.

    Published in:
    Leukemia & Lymphoma, 1996, v. 23, n. 1/2, p. 185, doi. 10.3109/10428199609054820
    By:
    • Arslan, Ö.;
    • Akan, H.;
    • Beksac, M.;
    • ÖZcan, M.;
    • Koc, H.;
    • Ilhan, O.;
    • Konuk, N.;
    • Uysal, A.
    Publication type:
    Article
    46
    47
    48
    49
    50